180 related articles for article (PubMed ID: 35965524)
1. Identification and Validation of METTL3-Related Molecules for Predicting Prognosis and Efficacy of Immunotherapy in Gastric Cancer Based on m6A Methylome and Transcriptome Sequencing Analysis.
Chen S; Su X; Wang J; Zheng N; Tang Y; Peng G; Dong R; Lu F; Liu M; Zhao Y; Wu H
Front Oncol; 2022; 12():935239. PubMed ID: 35965524
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
3. Integrative proteomics and m6A microarray analyses of the signatures induced by METTL3 reveals prognostically significant in gastric cancer by affecting cellular metabolism.
Peng G; Chen S; Zheng N; Tang Y; Su X; Wang J; Dong R; Wu D; Hu M; Zhao Y; Liu M; Wu H
Front Oncol; 2022; 12():996329. PubMed ID: 36465351
[TBL] [Abstract][Full Text] [Related]
4. Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
Liu T; Yang S; Sui J; Xu SY; Cheng YP; Shen B; Zhang Y; Zhang XM; Yin LH; Pu YP; Liang GY
J Cell Physiol; 2020 Jan; 235(1):548-562. PubMed ID: 31232471
[TBL] [Abstract][Full Text] [Related]
5. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
Front Genet; 2022; 13():872186. PubMed ID: 35937991
[No Abstract] [Full Text] [Related]
6. Depicting the Profile of METTL3-Mediated lncRNA m6A Modification Variants and Identified SNHG7 as a Prognostic Indicator of MNNG-Induced Gastric Cancer.
Liu T; Feng Y; Yang S; Ge Y; Zhang T; Li J; Li C; Ruan Y; Luo B; Liang G
Toxics; 2023 Nov; 11(11):. PubMed ID: 37999596
[TBL] [Abstract][Full Text] [Related]
7. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
[TBL] [Abstract][Full Text] [Related]
8. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma.
Shen S; Yan J; Zhang Y; Dong Z; Xing J; He Y
Ann Transl Med; 2021 Jan; 9(1):59. PubMed ID: 33553352
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
10. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
11. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
Meijing Z; Tianhang L; Biao Y
Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
[No Abstract] [Full Text] [Related]
12. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
13. Expression profiles and prognostic roles of m6A writers, erasers and readers in gastric cancer.
Jing JJ; Zhao X; Li H; Sun LP; Yuan Y
Future Oncol; 2021 Jul; 17(20):2605-2620. PubMed ID: 33878934
[TBL] [Abstract][Full Text] [Related]
14. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
[No Abstract] [Full Text] [Related]
15. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
Front Immunol; 2021; 12():769425. PubMed ID: 34804059
[TBL] [Abstract][Full Text] [Related]
16. Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets.
Zhou Y; Yin Z; Hou B; Yu M; Chen R; Jin H; Jian Z
Cancer Manag Res; 2019; 11():3921-3931. PubMed ID: 31118805
[No Abstract] [Full Text] [Related]
17. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma.
Qi LW; Jia JH; Jiang CH; Hu JM
Front Genet; 2020; 11():614566. PubMed ID: 33519919
[TBL] [Abstract][Full Text] [Related]
18. METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway.
Yang DD; Chen ZH; Yu K; Lu JH; Wu QN; Wang Y; Ju HQ; Xu RH; Liu ZX; Zeng ZL
Front Oncol; 2020; 10():115. PubMed ID: 32175271
[TBL] [Abstract][Full Text] [Related]
19. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y
Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544
[TBL] [Abstract][Full Text] [Related]
20. Identification and Validation of an m6A Modification of JAK-STAT Signaling Pathway-Related Prognostic Prediction Model in Gastric Cancer.
Jiang F; Chen X; Shen Y; Shen X
Front Genet; 2022; 13():891744. PubMed ID: 35928449
[No Abstract] [Full Text] [Related]
[Next] [New Search]
